Dova Pharmaceuticals (DOVA) Misses Q3 EPS by 6c

Dova Pharmaceuticals (NASDAQ: DOVA) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Dova Pharmaceuticals (DOVA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79